# OnCo record paper-conko-001-adjuvant-gemcitabine-observation-jama-2007 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-conko-001-adjuvant-gemcitabine-observation-jama-2007/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-conko-001-adjuvant-gemcitabine-observation-jama-2007" ;
  schema:name "Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial"@en ;
  schema:description "The 2007 German and Austrian trial in which six months of gemcitabine after surgery roughly doubled the time before the cancer came back, making gemcitabine the standard after resection until 2017."@en ;
  schema:url <https://onco.cc/key-papers/paper-conko-001-adjuvant-gemcitabine-observation-jama-2007/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jama.297.3.267>, <https://pubmed.ncbi.nlm.nih.gov/17227978/> ;
  onco:tag "pancreatic-evidence" ;
  schema:sameAs <https://doi.org/10.1001/jama.297.3.267> ;
  schema:datePublished "2007"^^xsd:gYear ;
  schema:author "Oettle H, Post S, Neuhaus P, et al." ;
  onco:related <https://onco.cc/key-papers/paper-conko-001-adjuvant-gemcitabine-long-term-oettle-jama-2013/>, <https://onco.cc/key-papers/paper-espac-1-chemoradiotherapy-chemotherapy-resected-pancreatic-nejm-2004/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/resectable-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine/> ;
  onco:institutions <https://onco.cc/institutions/charite/> ;
  onco:trials <https://onco.cc/trials/conko-001/> ;
  onco:journals <https://onco.cc/journals/jama/> .